-
24 December 2011
KARO BIO ENTERS COLLABORATION WITH PFIZER TO DISCOVER AND DEVELOP INNOVATIVE DRUGS FOR AUTOIMMUNE DISEASES
STOCKHOLM, 24 December 2011 - Karo Bio AB (publ) has entered into a research collaboration agreement with Pfizer Inc., to discover and develop novel small molecule RORgamma modulators for the treatment of autoimmune diseases.
-
01 November 2011
KARO BIO ISSUES NOTICE OF REDUNDANCY FOR 25 EMPLOYEES
-
25 October 2011
KARO BIO PREPARES SPIN-OFF OF PRECLINICAL DEVELOPMENT
STOCKHOLM, 25 October 2011 - Karo Bio AB (publ) is preparing a better allocation of resources and competences by spinning off the company’s preclinical activities. This part will therefore be transferred into a subsidiary that is intended to become autonomous in operations as well as by ownership. The subsidiary will be proposed to assume the name Karo Bio.
-
25 October 2011
INTERIM REPORT JANUARY–SEPTEMBER 2011
-
24 October 2011
Per Bengtsson appointed CEO
STOCKHOLM, October 24, 2011 – The Board of Directors in Karo Bio AB (publ) has appointed Per Bengtsson, CEO. Per Bengtsson has been acting CEO and member of the Board since May.
-
18 October 2011
PRESENTATION OF THE INTERIM REPORT
-
04 October 2011
FIRST PATIENT INCLUDED IN PHASE III STUDY
STOCKHOLM, 4 October 2011 - The first patient has now been included in Karo Bio's phase III trial (the AKKA study) with eprotirome. A total of 630 patients with the hereditary condition HeFH will be studied for safety, and to confirm the beneficial effects on LDL-cholesterol that has been shown previously.
-
30 September 2011
Changes in management of Karo Bio AB
STOCKHOLM, September 30, 2011 - Karo Bio AB (publ) today announced that Chief Financial Officer, Erika Söderberg Johnson, leaves her position.
-
19 September 2011
GO-AHEAD FOR KARO BIO PHASE III STUDY
STOCKHOLM, September 19, 2011 - Karo Bio AB (publ) has received approval from national regulatory authorities to start its phase III patient study with eprotirome, enabling the study to start as planned with an Investigators meeting in September.
-
17 August 2011
CHANGES IN MANAGEMENT OF KARO BIO AB
STOCKHOLM, August 17, 2011 - Karo Bio AB (publ) today announced that Jens Kristensen, Chief Medical Officer and Vice President Preclinical Development and Regulatory affairs, leaves his position.
-
13 July 2011
INTERIM REPORT JANUARY–JUNE 2011
-
08 July 2011
PRESENTATION OF THE INTERIM REPORT JANUARY- JUNE 2011
-
24 May 2011
KARO BIO AB APPOINTS PER BENGTSSON AS ACTING PRESIDENT AND CEO
STOCKHOLM, May 24, 2011 – Karo Bio AB (publ) today announces that the Board of Karo Bio has appointed Per Bengtsson as acting President and CEO of the company.
-
23 May 2011
KARO BIO’S CEO, FREDRIK LINDGREN, LEAVES
Stockholm, May 23, 2011 – Karo Bio AB (publ) communicates today that Fredrik Lindgren will leave his position as CEO of the company. A new CEO will be appointed by the board at the board meeting on May 24, 2011.
-
16 May 2011
KARO BIO: OPPORTUNITIES FOR ER-BETA COMPOUNDS PRESENTED AT SCIENTIFIC SYMPOSIUM
STOCKHOLM, May 16, 2011 – Karo Bio AB (publ) is organizing a symposium in Stockholm on May 16-17, where key researchers from the industry and the academic community present and discuss the frontier of research in the field of estrogen receptor beta (ER-beta) and its therapeutic applications. At the symposium, promising results for ER-beta selective compounds in preclinical models of mul…
-
04 May 2011
PRESS RELEASE FROM CONTINUED ANNUAL GENERAL MEETING OF KARO BIO AB (PUBL)
Stockholm, May 4th, 2011 – The Annual General Meeting of Karo Bio AB (publ) on April 27th, 2011 resolved to adjourn before the election of Board of Directors. The Annual General Meeting was resumed on May 4th, 2011 at 17.00 CET. The resumed Annual General Meeting resolved, among other things, on election of Board of Directors, Chairman of the Board and nominating committee as well as on…
-
04 May 2011
Shareholder proposal about election of board of directors and nominating committee in Karo Bio AB (PUBL)
STOCKHOLM, May 4, 2011 – A group of shareholders in Karo Bio AB (publ) has presented a proposal about a new board of directors and a new nominating committee, which the group of shareholders intend to propose for election at the annual general meeting, to be resumed on Wednesday May 4, 2011 at 17.00 CET at Klara Konferens, Vattugatan 6 in Stockholm.
-
02 May 2011
CONTINUED ANNUAL GENERAL MEETING OF Karo Bio AB (PUBL)
STOCKHOLM, May 2, 2011 – The annual general meeting of Karo Bio AB (publ) decided on April 27th, 2011 to adjourn prior to the election of board of directors. The Annual General Meeting decided to resume on Wednesday May 4th, 2011 at 17.00 CET. The continued Annual General Meeting will take place at Klara Konferens, with address Vattugatan 6, Stockholm.
-
28 April 2011
THE ANNUAL GENERAL MEETING OF KARO BIO AB (PUBL) ADJOURNED
STOCKHOLM, April 28, 2011 – The annual general meeting of Karo Bio AB (publ) on April 27 2011 resolved to adjourn before the election of board of directors. The general meeting resolved to resume the meeting in a week, Wednesday May 4, 2011 at 17.00 CET.
-
27 April 2011
INTERIM REPORT JANUARY–MARCH 2011
-
26 April 2011
KARO BIO AND ALKEM LABORATORIES LTD COLLABORATE TO DEVELOP EPROTIROME
STOCKHOLM, April 26, 2011 – Karo Bio AB (publ) and Alkem Laboratories Ltd have entered into a collaboration and license agreement regarding eprotirome, currently in late-stage clinical testing for dyslipidemia. Karo Bio will grant Alkem rights to commercialize eprotirome in India and certain other countries. Alkem will participate in Karo Bio’s phase III program for eprotirome by condu…
-
25 March 2011
Annual Report 2010
-
25 March 2011
KARO BIO’S ANNUAL REPORT NOW AVAILABLE
Stockholm, March 25, 2011 – Karo Bio AB’s annual report for 2010 is as of today available on the company’s website www.karobio.com (http://www.karobio.com/).
-
25 March 2011
NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS OF KARO BIO
Stockholm, March 25, 2011 – The annual general meeting of Karo Bio AB (publ) will be held on Wednesday April 27, 2011, at 5:00 pm CET in Klarasalen, Klara Konferens, Vattugatan 6, Stockholm, Sweden.
-
21 March 2011
KARO BIO AND ZYDUS CADILA extend RESEARCH AGREEMENT
Stockholm, March 21, 2011 – Karo Bio AB (publ) (Reuters: KARO.ST) and Zydus Cadila have agreed to extend their research collaboration with the purpose to discover and develop novel anti-inflammatory drug compounds which affect glucocorticoid receptors in a selective manner.
-
09 February 2011
INTERIM REPORT JANUARY–DECEMBER 2010
The January – December period and fourth quarter 2010 in brief
-
31 January 2011
CHANGE IN NUMBER OF SHARES AND VOTES IN KARO BIO (PUBL)
